Результаты поиска

Translational progress on tumor biomarkers.

There is an urgent need to apply basic research achievements to the clinic. In particular, mechanistic studies should be developed by bench researchers, depending upon clinical demands, in order to improve the survival and quality of life of cancer patients. To date, translational medicine has been addressed in cancer biology, particularly in the identification and characterization of novel tumor biomarkers. This review focuses on the recent achievements and clinical application prospects in tumor biomarkers based on translational medicine.

Совпадение в полном тексте источника
… Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328:240–243. doi: 10.1126/science.1183424. Cho-Park PF, Steller H. Proteasome regulation by ADP-ribosylation. Cell. 2013;153:614–627. doi: 10.1016/j.cell.2013.03.040. …

Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.

BACKGROUND: Chemotherapy remains a foundation of cancer care but is limited by multidrug resistance, systemic toxicities, and suboptimal selectivity, prompting interest in adjunctive strategies that improve efficacy and tolerability without adding significant burden to patients or healthcare systems. AIMS/OBJECTIVES: This review highlights evidence on natural bioactive compounds, including polyphenols, alkaloids, terpenoids, and fungal metabolites, as adjuvants to standard chemotherapeutics, with objectives to: first, delineate mechanisms by which these agents enhance cytotoxic efficacy and o

Совпадение в полном тексте источника
… Other effective Pin1 inhibitors that help reduce tumor resistance include EGCG, all-trans retinoic acid (ARTA), and arsenic trioxide (ATO) [ 231 ]. …

The innate defenders: a review of natural killer cell immunotherapies in cancer.

Cancer is a condition that has been with us for centuries; however, the therapies that have been developed are often associated with significant toxicity and various side effects. Recent advances in immunology have revealed the potential of the immune system to fight cancer, leading to the emergence of immunotherapy. This review focuses on Natural Killer (NK) cells, innate immune effectors with a remarkable ability to directly kill cancer cells. We will explore the historical context of cancer treatment, the nature of NK cells, and the ways they have been developed to enhance their anti-tumor

Совпадение в полном тексте источника
… Arsenic trioxide (ATO) has been shown to increase the expression of NKG2D ligands, leading to enhanced NK cell recognition and killing of AML cells. … Arsenic trioxide enhances the NK cell cytotoxicity against acute promyelocytic leukemia while simultaneously inhibiting its bio-genesis . Front Immunol . ( 2018 ) 9 : 1357 . doi: 10.3389/fimmu.2018.01357 29963052 PMC6010577 55 Liem NT Van Phong N Kien NT Anh BV Huyen TL Thao CT . …

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hemato

Совпадение в полном тексте источника
… However, a very recent retrospective trial pointed at the significant risk of VZV reactivation in patients with acute promyelocytic leukaemia treated with arsenic trioxide: In 112 patients, disease by reactivation of VZV occurred in 17.5% of patients (including one patient with VZV encephalitis) without … Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia. Leuk Lymphoma. 2021;62(3):696–702. doi: 10.1080/10428194.2020.1838507. 84. Logan C, Koura D, Taplitz R. Updates in infection risk and management in acute leukemia. …

Токсичность тяжелых металлов в клиническом и экологическом здравоохранении: источники, механизмы, диагностика и научно обоснованное управление ртутью, свинцом, кадмием и арсеником.

Тяжелые металлы, включая ртуть (Hg), свинец (Pb), кадмий (Cd) и мышьяк (As), по-прежнему остаются значительными глобальными токсинами в силу их экологической стойкости, широкомасштабного антропогенного высвобождения и серьезного биологического воздействия. Этот обзор укрепляет нынешнее понимание их природных и промышленных источников, круговорота окружающей среды, маршрутов воздействия на человека и факторов уязвимости на уровне населения. Она охватывает их токсикокинетику и токсикодинамику, делая акцент на специфических для каждого вида механизмах поглощения, распределения и травмирования, вк

Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.

Autophagy is a multistep catabolic process through which misfolded, aggregated or mutated proteins and damaged organelles are internalized in membrane vesicles called autophagosomes and ultimately fused to lysosomes for degradation of sequestered components. The multistep nature of the process offers multiple regulation points prone to be deregulated and cause different human diseases but also offers multiple targetable points for designing therapeutic strategies. Cancer cells have evolved to use autophagy as an adaptive mechanism to survive under extremely stressful conditions within the tumo

Совпадение в полном тексте источника
… Drugs such as tamoxifen [ 64 ], temozolomide [ 65 ], resveratrol [ 66 ] or arsenic trioxide induce protective autophagy in cancer cells of the breast, prostate, colon and malignant glioma [ 67 ]. Radiotherapy has also shown induction of protective autophagy [ 68 ]. … Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2005;24:980–991. doi: 10.1038/sj.onc.1208095. 68. Ito H., Daido S., Kanzawa T., Kondo S., Kondo Y. …

Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.

BackgroundIntegrated bioinformatics approaches were used to identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer (TNBC).MethodsMicroarray (164 early-stage, 33 advanced-stage, and 53 normal samples) and RNA-seq (113 normal, 163 early-stage, and 30 advanced-stage TNBC samples) datasets were analyzed. Differentially expressed genes (DEGs) were identified, followed by co-expression analysis using Weighted Gene Co-expression Network Analysis (WGCNA) and protein-protein interaction analysis using the STRING database. miRNA co-regulation was evaluated us

Совпадение в полном тексте источника
… Stage | Gene | Conventional drugs | Repurposing drugs | Current clinical use Early | | | DNAJC6 | Doxorubicin | Cyclosporine Sunitinib | anti-rheumatoid arthritis Anti-cancer SKP2 | Cisplatin Afuresertib Doxorubicin Estradiol Methotrexate Raloxifene Hydrochloride | Arsenic trioxide Azathioprine Bortezomib … For early-stage TNBC, agents such as cyclosporine, sunitinib, arsenic trioxide, and isotretinoin demonstrated the potential to modulate key genes ( DNAJC6, SKP2, MOCOS , and NCAPD2 ), targeting cancer-related pathways through mechanisms like angiogenesis inhibition, DNA damage induction, and epigenetic …

[Patient-reported outcome and its application in hematological neoplasm].

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J] N Engl J Med. 2013;369(2):111–121. doi: 10.1056/NEJMoa1300874. 34. Burnett AK, Russell NH, Hills RK, et al. … Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial[J] Lancet Oncol. 2015;16(13):1295–1305. doi: 10.1016/S1470-2045(15)00193-X. 35. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. …

Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.

Iron and ascorbic acid (vitamin C) are essential nutrients for the normal growth and development of humans, and their deficiency can result in serious diseases. Their interaction is of nutritional, physiological, pharmacological and toxicological interest, with major implications in health and disease. Millions of people are using pharmaceutical and nutraceutical preparations of these two nutrients, including ferrous ascorbate for the treatment of iron deficiency anaemia and ascorbate combination with deferoxamine for increasing iron excretion in iron overload. The main function and use of vit

Совпадение в полном тексте источника
… Arsenic Trioxide/Ascorbic Acid Therapy in Patients with Refractory Metastatic Colorectal Carcinoma: A Clinical Experience. Acta Oncol. (Madr.) 2007;46:557–561. doi: 10.1080/02841860601042456. 26. Bael T.E., Peterson B.L., Gollob J.A. … Phase II Trial of Arsenic Trioxide and Ascorbic Acid with Temozolomide in Patients with Metastatic Melanoma with or Without Central Nervous System Metastases. Melanoma Res. 2008;18:147–151. doi: 10.1097/CMR.0b013e3282f2a7ae. 27. …

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatme

Совпадение в полном тексте источника
… In particular, some case reports showed that arsenic trioxide (ATO), well-known for APL treatment, may overcome HH inhibitors resistance in combination with itraconazole in patients with BCC [ 85 ]. … Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol. 2016;152:452–456. doi: 10.1001/jamadermatol.2015.5473. 86. Goldman S.L., Hassan C., Khunte M., Soldatenko A., Jong Y., Afshinnekoo E., Mason C.E. …

Targeting Metabolic Reprogramming in Acute Myeloid Leukemia.

The cancer metabolic reprogramming allows the maintenance of tumor proliferation, expansion and survival by altering key bioenergetics, biosynthetic and redox functions to meet the higher demands of tumor cells. In addition, several metabolites are also needed to perform signaling functions that further promote tumor growth and progression. These metabolic alterations have been exploited in different cancers, including acute myeloid leukemia, as novel therapeutic strategies both in preclinical models and clinical trials. Here, we review the complexity of acute myeloid leukemia (AML) metabolism

Совпадение в полном тексте источника
… The high glycolytic profile has been shown to be important for chemotherapy response, having been found to confer greater resistance to apoptosis induced by All-Trans-Retinoic-Acid (ATRA) and arsenic trioxide in primary blasts and AML cell lines, besides having an impact on the clinical prognosis [ 14 … Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells. Leuk. Res. 2008;32:327–333. doi: 10.1016/j.leukres.2007.04.014. 15. Song K., Li M., Xu X.J., Xuan L., Huang G.N., Song X.L., Liu Q.F. …

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.

In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either favoring anti-tumor activity or tumor promotion. However, if thiazolidinediones are combined with additional regulatory active drugs, so-called 'master modulators' of tumors, i.e., transcriptional modulators, metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs, etc., the results indicate clinically relevant communicative reprogram

Совпадение в полном тексте источника
… Pro-anakoinotic therapeutic tools (examples) | Transcriptional modulators, nuclear receptor agonists and antagonists, metronomic low-dose chemotherapy, cyclooxygenase-2 inhibitors, IMiDs, arsenic trioxide, liposomal encapsulated small oligonucleotide encoding small activating RNAs, etc. … Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J. Clin. Oncol. 2017;35:605–612. doi: 10.1200/JCO.2016.67.1982. 12. …

Mucocutaneous Findings in Hematolymphoid Neoplasms: An Observational Study.

BackgroundCutaneous manifestations of hematological neoplasms can be divided into three broad categories - direct infiltration, paraneoplastic conditions, and those due to the treatment of hematological cancers.ObjectivesTo study the frequency and patterns of mucocutaneous manifestations in patients with hematolymphoid neoplasms and those due to chemotherapy.Materials and methodsThis was an observational study done with 172 patients. Categorization of mucocutaneous manifestations was done into malignancy-associated and chemotherapeutic drugs-associated and data was analyzed.ResultsOut of a tot

Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection/administration of cytarabine. Second case report.

We show for the second time that intramarrow injection/administration of chemotherapeutic agents such as cytarabine (Ara-C) can be used safely and effectively and is associated with no toxicity, promising antileukemic activity and possible improved survival.

Совпадение в полном тексте источника
… Prospective randomized clinical trials are warranted to compare other conventional therapies such as low dose Ara‐C alone versus LDAC in combination with all‐trans retinoic acid (ATRA) and/or arsenic trioxide (ATO) in order to clarify the role of such treatments in elderly patients with AML 21 . …

Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.

Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on the impact of t-AML on long-term outcome in AML. Therefore, we retrospectively analyzed clinical and biological characteristics of 1133 AML patients (225 t-AML patients and 908 de novo AML patients) with a median follow-up of 81.8 months. T-AML patients showed more adverse genetic alterations, higher age and more comorbidities as compared to de novo AML. Median OS in intensively treated t-AML patients was 13.7 months as compared to 39.4 months in de novo AML (p < 0.001). Wit

Совпадение в полном тексте источника
… Kayser S Krzykalla J Elliott MA Norsworthy K Gonzales P Hills RK Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide Leukemia 2017 31 2347 54 10.1038/leu.2017.92 28322237 PMC6037311 Kayser S, Krzykalla J, Elliott … Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia 2017;31:2347–54. 28322237 10.1038/leu.2017.92 PMC6037311 41. …

Лейкемия в период беременности: диагностика и терапевтический подход (обзор).

Цель настоящего исследования заключается в оценке эпидемиологических, диагностических и терапевтических данных о гематологических заболеваниях в период беременности. Лейкемия в период беременности встречается редко, а литературные данные не являются обширными. Факторы риска, эпидемиология и патогенез этих заболеваний не разработаны в полной мере. Кроме того, имеется подробный доклад о осложнениях в период беременности и об общем (на три месяца) лечении этих заболеваний, в частности о стратегии их лечения. В настоящем исследовании описывается возможность обеспечения в будущем беременности у жен

Совпадение в полном тексте источника
… Since 2013, a drug combination of arsenic trioxide with ATRA can offer higher cure rates and fewer relapses compared to AIDA, and consists of a chemo-free therapeutic approach to the disease ( 10 ). … Arsenic trioxide is teratogenic and should be avoided in all three trimesters of pregnancy ( 13 , 14 ). Management of APL in the second and third trimesters of pregnancy During the second and third trimesters, ATRA and chemotherapy can exclusively be administered after childbirth. …

Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

IntroductionThe global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.Material and methodsIn this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the

Molecular Characterization of a First-in-Human Clinical Response to Nimesulide in Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a hematologic malignancy associated with high morbidity and mortality. Here we describe a case of a patient with AML who presented a partial response after utilization of the non-steroidal anti-inflammatory drug nimesulide. The response was characterized by complete clearance of peripheral blood blasts and an 82% decrease of bone marrow blasts associated with myeloblast differentiation. We have then shown that nimesulide induces in vitro cell death and cell cycle arrest in all AML cell lines (HL-60, THP-1, OCI-AML2, and OCI-AML3). Weighted Correlation Network An

Совпадение в полном тексте источника
… Induction of Autophagic Cell Death in Malignant Glioma Cells by Arsenic Trioxide . Cancer Res ( 2003 ) 63 ( 9 ): 2103–8 . 12727826 33 Riffelmacher T Simon AK . Mechanistic Roles of Autophagy in Hematopoietic Differentiation . …

Targeting cancer stem cells in drug discovery: Current state and future perspectives.

In recent decades, cancer stem cells (CSCs) have been increasingly identified in many malignancies. CSC-related signaling pathways and their functions provide new strategies for treating cancer. The aberrant activation of related signaling pathways (e.g., Wnt, Notch, and Hedgehog pathways) has been linked to multiple types of malignant tumors, which makes these pathways attractive targets for cancer therapy. CSCs display many characteristic features, such as self-renewal, differentiation, high tumorigenicity, and drug resistance. Therefore, there is an urgent need to develop new therapeutic st

Совпадение в полном тексте источника
… Arsenic trioxide (ATO) is an FDA-approved drug for the treatment of acute promyelocytic leukemia, and ATO was later discovered to be a Gli transcription factor inhibitor and entered as such into phase II clinical trials[ 112 ]. … trioxide) in the treatment of myelodysplastic syndromes Leukemia 2003 17 1499 1507 12886236 10.1038/sj.leu.2403021 113 Beauchamp EM Ringer L Bulut G Sajwan KP Hall MD Lee YC Peaceman D Ozdemirli M Rodriguez O Macdonald TJ Albanese C Toretsky JA Uren A Arsenic trioxide inhibits human cancer cell growth …

The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles.

Lung cancer is the leading cause of cancer-related mortality worldwide. Although the PI3K/Akt/mTOR signaling pathway has recently been considered as one of the most altered molecular pathways in this malignancy, few articles reviewed the task. In this review, we aim to summarize the original data obtained from international research laboratories on the oncogenic alterations in each component of the PI3K/Akt/mTOR pathway in lung cancer. This review also responds to questions on how aberrant activation in this axis contributes to uncontrolled growth, drug resistance, sustained angiogenesis, as w